NCT00746174View on ClinicalTrials.gov

Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone

PHASE4CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

February 29, 2008

Conditions

Insulin Sensitivity

Interventions

DRUG

Rosiglitazone

Rosiglitazone 8mg PO daily for 16 weeks

DRUG

Placebo

Placebo 1 tablet PO daily for 16 weeks

Trial Locations (1)

75390

University of Texas Southwestern Medical Center at Dallas, Dallas

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER